Radioligand-Antibody Conjugates: Integrating Antibody Engineering, Chelator Chemistry, and Radioligands for Precision Theranosis.
1/5 보강
Radioligand-antibody conjugates (RadioBodies), also known as radiolabeled antibodies, represent an emerging class that enables targeted delivery of radionuclides to tumor cells using antibodies.
APA
Khandave PY, Gudavalekar PU, et al. (2026). Radioligand-Antibody Conjugates: Integrating Antibody Engineering, Chelator Chemistry, and Radioligands for Precision Theranosis.. Molecular diagnosis & therapy, 30(2), 259-280. https://doi.org/10.1007/s40291-025-00825-2
MLA
Khandave PY, et al.. "Radioligand-Antibody Conjugates: Integrating Antibody Engineering, Chelator Chemistry, and Radioligands for Precision Theranosis.." Molecular diagnosis & therapy, vol. 30, no. 2, 2026, pp. 259-280.
PMID
41413364 ↗
Abstract 한글 요약
Radioligand-antibody conjugates (RadioBodies), also known as radiolabeled antibodies, represent an emerging class that enables targeted delivery of radionuclides to tumor cells using antibodies. Conventional antibodies (full-length antibodies) and nonconventional antibodies (antibody fragments) are ideal agents for targeted delivery of radionuclides to tumor sites, owing to their high affinity and specificity. Antibody guides the radionuclide to a precise target, where it participates in killing of cancer cells (therapy) or helps with imaging (diagnosis). RadioBodies are yet to be effectively employed in cancer theranostics but have the potential for the same. Conventional antibodies have long circulatory half-lives, a feature that limits their application in diagnosis but is desirable for therapy. Using nonconventional antibodies (antibody fragments) offers the advantages of small size and removal of the Fc function, which reduces the serum half-life. In recent years, advances in antibody engineering, chelator chemistry and radionuclide technology have greatly facilitated the development of RadioBodies for desired applications. In this review, we discuss the roles of antibodies, chelators, and radionuclides in the clinical development of RadioBodies for cancer theranostics.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.